Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C

American Journal of Gastroenterology

Volumn 104, Issue 10, 2009, Pages 2439-2448

  John Baptiste, Ava A ^a,b,c   Tomlinson, George ^a,b,c,d   Hsu, Priscilla C ^e,f   Krajden, Mel ^e,f   Heathcote, E Jenny ^a,b   Laporte, Audrey ^a   Yoshida, Eric M ^f   Anderson, Frank H ^g   Krahn, Murray D ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Liver and Intestinal Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PEGETRON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ADULT; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; FEMALE; HEALTH STATUS; HEPATITIS C; HOUSEHOLD; HUMAN; HUMAN TISSUE; INTERVIEW; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL HEALTH; POSTAL MAIL; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; SUBSTANCE ABUSE; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD; VOLUNTEER; WORK; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY; STATISTICAL MODEL; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HEPATITIS C, CHRONIC; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 70350508341     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.346     Document Type: Article

References (37)

1. Kleinman L, Zodet MW, Hakim Z et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000; 9:499-508
2. Kramer L, Hofer H, Bauer E et al. Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS 2005; 19 (Suppl 3):S85-92
3. Thein HH, Maruff P, Krahn MD et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Medicine 2007; 8:520-528
4. Rodger AJ, Jolley D, Thompson SC et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999; 30:1299-1301
5. Zickmund S, Ho EY, Masuda M et al. They treated me like a leper ". Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003; 18:835-44
6. Dalgard O, Egeland A, Skaug K et al. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39:74-80
7. Fontana RJ, Hussain KB, Schwartz SM et al. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002; 36:401-407
8. Gallegos-Orozco JF, Fuentes AP, Gerardo Argueta J et al. Health-related quality of life and depression in patients with chronic hepatitis C. Arch Med Res 2003; 34:124-129
9. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27:431-438
10. Hussain KB, Fontana RJ, Moyer CA et al. Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. Am J Gastroenterol 2001; 96:2737-2744
11. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29:264-270
12. Ware JE Jr, Bayliss MS, Mannocchia M et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventionaltherapy Group. Hepatology 1999; 30:550-555
13. Hsu PC, Krajden M, Yoshida EM et al. Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver Int 2009; 29:449-458
14. Barber M, Stott DJ. Validity of the Telephone Interview for Cognitive Status (TICS) in post-stroke subjects. Int J Geriatr Psychiatry 2004; 19:75-79
15. Debling D, Amelang M, Hasselbach P et al. Assessment of cognitive status in the elderly using telephone interviews. Z Gerontol Geriatr 2005; 38:360-367
16. Chong CA, Gulamhussein A, Heathcote EJ et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98:630-638
17. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383
18. Greenfield S, Apolone G, McNeil BJ et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993; 31:141-154
19. Ware JE Jr, Snow KK, Kosinski M et al. SF-36 Health Survey Manual and Interpretation Guide. New England Medical Centre, The Health Institute: Boston, MA, 1993
20. Bayliss MS, Gandek B, Bungay KM et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7:39-55
21. Bayliss MS. Methods in outcomes research in hepatology: definitions and domains of quality of life. Hepatology 1999; 29:3S-6S
22. Feeny D, Furlong W, Boyle M et al. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995; 7:490-502
23. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Healthe con 2002; 21:271-292
24. Kharroubi SA, Brazier JE, Roberts J et al. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Healthe con 2007; 26:597-612
25. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40:593-603
26. Sanmartin C, Berthelot JM, Ng E et al. Comparing health and health care use in Canada and the United States. Health Aff airs 2006; 25:1133-1142
27. Hopman WM, Towheed T, Anastassiades T et al. Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.[see comment]. CMAJ 2000; 163:265-271
28. Fryback DG, Dunham NC, Palta M et al. US norms for six generic healthrelated quality-of-life indexes from the National Health Measurement study. Med Care 2007; 45:1162-1170
29. Rasenack J, Zeuzem S, Feinman SV et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics 2003; 21:341-349 (Pubitemid 36403438)
30. Helbling B, Overbeck K, Gonvers JJ et al. Host-rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57:1597-1603
31. Thein HH, Krahn M, Kaldor JM et al. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100:643-651
32. Wright M, Grieve R, Roberts J et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess (Winchester, England) 2006; 10:1-113
33. Bianchi G, Loguercio C, Sgarbi D et al. Reduced quality of life in patients with chronic hepatitis C: Effects of interferon treatment. Dig Liver Dis 2000; 32:398-405
34. Zacks S, Beavers K, The odore D et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol 2006; 40:220-224
35. McHutchison JG, Ware JE Jr, Bayliss MS et al. The Effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34:140-147
36. Witkos M, Yi QL, Heathcote J et al. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol 2006; 20:107-111
37. Grebely J, Genoway K, Khara M et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18:437-43.